Overall rank by patents
#2,138
Across all tracked assignees
USPTO PatentsView assignee record - 184 granted patents across 40 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: H04L (TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION).
The verdict
Adtran holds 184 US patents across 40 technology areas, rank #2,138 of 50,000 tracked assignees.
Adtran, Inc. has been granted 184 US utility patents between 2015 and 2025, placing Adtran, Inc. at rank #2,138 across all assignees tracked by PlainPatent. This portfolio spans 40 distinct Cooperative Patent Classification (CPC) subclasses, averaging 19.0 claims per patent with primary concentration in H04L (TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION). As a US Corporation, Adtran, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Adtran sits between Perkinelmer Health Sciences, Inc. (185 patents, rank #2,134) and Gates Corporation (184 patents, rank #2,142) - the closest US assignees by grant volume. The composite Innovation Score of 54.3/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 46 grants, compared with 138 in the 2015–2019 window, a -67% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Adtran, Inc.'s 19.0 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while a multi-domain presence across 40 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Adtran, Inc. against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
PerkinElmer Health Sciences, Inc.
185 patents
RAYTHEON BBN TECHNOLOGIES CORP.
185 patents
ZEDEL
185 patents
ASICS CORPORATION
184 patents
Dart Industries Inc.
184 patents
ETH ZURICH
184 patents
FOUNDATION OF SOONGSIL UNIVERSITY-INDUSTRY COOPERATION
184 patents
Gates Corporation
184 patents
Adtran, Inc.
184 patents
What this shows Adtran holds 184 patents at rank #2,138, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #2,138 in granted patent volume.
Other assignees with the most granted patents in Adtran's primary technology class.
Adtran's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
54 Top 8% higher than 92% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 33 | 17.9% |
| 2016 | 33 | 17.9% |
| 2017 | 29 | 15.8% |
| 2018 | 26 | 14.1% |
| 2019 | 17 | 9.2% |
| 2020 | 17 | 9.2% |
| 2021 | 6 | 3.3% |
| 2022 | 4 | 2.2% |
| 2023 | 6 | 3.3% |
| 2024 | 5 | 2.7% |
| 2025 | 8 | 4.3% |
Top 15 of 40 technology areas
Overall rank by patents
#2,138
Across all tracked assignees
54.3 out of 100
How to use this portfolio
Adtran's 184 grants land it in the top 8% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.